WO2009059802A1 - Dispositif à ballon gastrique auto-dégonflable - Google Patents

Dispositif à ballon gastrique auto-dégonflable Download PDF

Info

Publication number
WO2009059802A1
WO2009059802A1 PCT/EP2008/009603 EP2008009603W WO2009059802A1 WO 2009059802 A1 WO2009059802 A1 WO 2009059802A1 EP 2008009603 W EP2008009603 W EP 2008009603W WO 2009059802 A1 WO2009059802 A1 WO 2009059802A1
Authority
WO
WIPO (PCT)
Prior art keywords
self
deflating
passage
biodegradable
balloon device
Prior art date
Application number
PCT/EP2008/009603
Other languages
English (en)
Inventor
Venera Khafizova
Original Assignee
Venera Khafizova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venera Khafizova filed Critical Venera Khafizova
Publication of WO2009059802A1 publication Critical patent/WO2009059802A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013—Implantable devices or invasive measures
    • A61F5/0036—Intragastrical devices

Definitions

  • the present invention is concerned with new and improved self-deflating gastric balloons devices, more particularly orally ingested self-deflating gastric balloon devices.
  • Obesity is the primary health problem in the United States today. The complications of obesity cost approximately $60 billion a year. There is a clear need and desire to provide effective, safe and convenient methods and means to treat patients to reduce or prevent obesity.
  • gastric also called intragastric
  • Their use reduces caloric intake by reducing the volume of food that can be accommodated by the stomach of a patient.
  • Food volume, or caloric mass is the overall reason for weight gain to begin with.
  • caloric intake exceeds caloric need, weight is gained.
  • the gastric balloon takes up stomach volume (or, increases "dead space") in the stomach so that the caloric intake is reduced. The balloon simply takes up space that otherwise could be taken up by food.
  • the patient requires sedation under general anaesthesia for the procedure.
  • the balloon was inflated via the catheter with either air or liquid. Once the desired level of inflation is achieved, the catheter is removed.
  • the balloon remains in the stomach for several months and the patient can achieve some weight loss benefit.
  • the invention suffers the significant disadvantage that in order to remove the balloon, the patient must be sedated again under general anaesthesia, a catheter inserted oesophageally having at its end a grasping tool, the balloon punctured to empty its contents, and the deflated balloon retrieved using the grasping tool.
  • US 4723547 describes an inflatable balloon designed to be inserted by a device similar to an endoscope.
  • the balloon is then filled externally via the endoscope-like tool, which is connected to the balloon by a pierceable self-sealing plug.
  • the balloon is disconnected from its filling device by withdrawal of the needle from the septum using the endoscope-like device, which retracts the needle into the endoscope- like device end. This balloon is not designed to be swallowed.
  • US 6981980 (Sampson) describes a swallowable and self-inflatable intragastric balloon. This invention self-inflates using bicarbonate within the balloon. The chemistry is activated just before swallowing by injecting acid into the interior of the balloon through a self-sealing valve. The carbon dioxide producing chemical inflates the balloon fully. The balloon remains in the stomach for a period of approximately one month. At that time, a biodegradable plug in the balloon wall begins to erode, thereby causing the balloon to deflate. Notably, there are substantial problems with the deflation, and the devices of US 6981980 are prone to slow deflation. Further, the design of a plug which directly holds back the internal pressure of the balloon like a cork is inherently easier to fail or leak than a device of the present invention (below) which uses a switch means to control deflation.
  • gastric balloon devices include the likes of BioEnterics Intragastric Balloon (BIB) produced by Inamed, Inc. (Inamed Health, Santa Barbara, CA, USA), the Heliosphere (Helioscopie SA, France) and the Ullorex Oral Intragastric Balloon (OIB) (Phagia Technology, Inc., Stuart, FL, USA).
  • BIOB BioEnterics Intragastric Balloon
  • OIB Ullorex Oral Intragastric Balloon
  • the BIB type product is a balloon that is placed in the stomach of a patient with an endoscope and filled with 400-800ml of saline. It is typically left in the stomach for 6-8 months and is then removed endoscopically.
  • the Heliosphere type product is an air-filled balloon of similar size to the BIB type product, and is inserted and removed endoscopically.
  • the OEB type product is a balloon that is encapsulated into a swallowable pill.
  • an activating liquid is injected into it.
  • the liquid activates a bicarbonate reaction that releases carbon dioxide gas into the balloon interior.
  • the balloon is fully inflated.
  • the life of the balloon is approximately 30 days before a bioabsorbable plug in the balloon wall dissolves, allowing it to deflate and to pass from the stomach naturally.
  • Oesophageal inflation is life-threatening, and with the Ullorex type devices, premature inflation or incomplete passage of the pill during swallowing cannot be guaranteed not to happen, meaning that swallowing procedures must take place in an endoscopically- equipped environment, in case emergency removal is required.
  • radiography - dumping syndrome can occur, also known as rapid gastric emptying, in which the stomach contents are transported into the small intestine too rapidly. Patients who have previously undergone surgery to remove or bypass part of the stomach are particularly prone to dumping condition. With the ingestion of a device that will inflate post-swallowing, the device must be located in the stomach when it inflates and not in the small intestine - if the device enters the small intestine then its inflation can be life-threatening. Thus, radiography is required to determine the location of the balloon, and surgical facilities are required in case emergency removal is required.
  • the automatically-inflating intragastric devices are also dependent upon the devices operating properly and the chemistry working properly. If there is a problem with the chemistry, a leak, or another mechanical failure, the balloon may only partially inflate. However, this would not be known unless radiography is used to determine inflation of the balloon or unless severe pain or further complications occur in the event of the partially-inflated balloon obstructing the pyloric sphincter or intestine.
  • the Ullorex type device uses a bio-absorbable plug which allows the balloon to deflate spontaneously in 3-4 weeks, and then the balloon is passed naturally. This spontaneous deflation and passage obviates the need for endoscopic removal of the device.
  • the plug in the balloon wall of the Ullorex type device is composed of a bio-absorbable polymer that degrades in 3-4 weeks under normal physiological conditions.
  • This plug is essentially a tiny "wall" in the balloon's surface that degrades spontaneously.
  • this presents a number of problems.
  • the plug in the wall of the Ullorex type device degrades in a gradual fashion. This means that a tiny pinhole develops first, followed by another pinhole, etc., until enough seepage occurs to deflate the balloon. This gradual leaking of the gaseous interior causes the balloon to deflate gradually over a period of many minutes to perhaps an hour. However, if deflation is too gradual, or if the patient's stomach is actively trying to push the balloon through the pyloric sphincter at the time of deflation, the balloon may only partially deflate and thus cause obstruction.
  • a self-deflating gastric balloon device comprising: (i) a balloon defining a balloon volume; and
  • valve means comprising:
  • valve body having attached to it said balloon and defining a passage having:
  • degradable switch means said switch means controlling fluid flow through said passage, such that with said switch means in a non-degraded state fluid flow through said passage is prevented, and with said switch means in a degraded state fluid flow through said passage can occur, said balloon remaining attached to said valve body.
  • the present invention seeks to overcome the prior art disadvantages and provides an improved self-deflating gastric balloon device.
  • the present invention provides a degradable switch means as part of valve means, and in contrast to the prior art devices, the degradable switch means does not form a direct path for fluid flow in the deflation process of the balloon. Rather, this element switches the valve means between open and closed states.
  • the switch means comprises a switch body and biodegradable securing means.
  • the balloon is attached to the valve body using any suitable means, including by use of adhesive, bonding agent, and RF welding.
  • valve bodies A wide range of valve arrangements are contemplated in the present invention.
  • the balloon remains attached to the valve body. This presents an advantage over prior art devices in that the valve body does not become separated from the balloon and so in the degraded state, fluid (for the present purposes, the term "fluid" means liquids and gases) is free to flow from the balloon through the valve means.
  • valve body will not cause a partially blocked state in which the rate of deflation of the balloon is limited, in contrast to other prior art devices which use a plug which upon degradation of a component part can move relative to the balloon and partially block any orifice, thus resulting in a slower than intended rate of deflation.
  • Slow deflation can be particularly problematic since a slowly deflating balloon can pass to the small intestine in a partially deflated state, causing blocking of the intestine or pyloric sphincter.
  • the biodegradable securing means comprises a biodegradable layer about at least a part of the periphery of said switch body.
  • the switch body plus biodegradable layer acts to block fluid flow through the passage.
  • the biodegradable layer is degraded and the switch body is able to move relative to the valve body and with a greater fluid pressure existing within the balloon than in the stomach (for example due to the balloon containing a pressurised gas or due to the stomach exerting mechanical pressure upon the balloon) the switch body is caused to exit the passage, thus allowing the flow of fluid from the balloon volume.
  • the biodegradable layer is located on the periphery of the switch body adjacent the inner wall of the passage so as to secure the switch body within the passage and block fluid flow through the passage.
  • the biodegradable layer has a toroidal shape. In certain embodiments, this is a ring shape.
  • the biodegradable securing means is non-toxic. More preferably, it is a gelatine, or a degradable polymer selected from the group consisting of: polylactic acid and polyglycolic acid.
  • the switch means is biodegradable.
  • the switch means is non- toxic.
  • the biodegradable securing means or switch means is biodegradable in stomach fluids (i.e. digestive/gastric fluids in the stomach) in a predetermined period of time.
  • the biodegradable securing means or switch means is biodegradable in a fluid in-use present in the device. Preferably, it enters a degraded state after a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 weeks. More preferably, the biodegradable securing means enters a degraded state after a period of 1 or 2 months.
  • biodegradable securing means or switch means can be provided to degrade in a chosen period of time.
  • the composition of the biodegradable material may be changed or provided in order that it will perform its role for a predetermined period of time.
  • a chosen thickness of biodegradable material can be provided.
  • the biodegradable securing means or switch means or biodegradable part thereof has a surface external to the balloon volume and other components.
  • the biodegradable securing means or switch means or biodegradable part thereof has a surface external to the balloon volume and other components.
  • the biodegradable securing means or switch means or biodegradable part thereof does not have a surface exposed to the balloon volume.
  • biodegradable securing means or switch means or biodegradable part thereof Depending upon the nature of the biodegradable securing means or switch means or biodegradable part thereof, and upon the nature of the fluid in-use contained in the balloon volume, it can be desirable to prevent fluid from the balloon volume contacting it since it may result in its partial degradation and a partially degraded state in which restricted fluid flow can occur through the passage via the partially degraded biodegradable securing means or switch means or biodegradable part thereof.
  • the biodegradable securing means or switch means or biodegradable part thereof has a surface exposed to the balloon volume.
  • a fluid having a known degradative effect upon the biodegradable securing means or switch means or biodegradable part thereof can be placed in the balloon volume.
  • the biodegradable securing means or switch means or biodegradable part thereof is preferably not degradable by stomach fluids.
  • the switch body comprises a head section and a tail anchor section
  • the biodegradable securing means comprises a biodegradable layer about at least a part of the periphery of the head section.
  • the valve means in the non-degraded state the head section with its biodegradable layer acts to block fluid flow through the passage.
  • the biodegradable layer In the degraded state, the biodegradable layer is degraded and the switch body is able to move relative to the valve body and in-use is caused to exit the passage, thus allowing the flow of fluid from the balloon volume.
  • the tail anchor section ensures that the switch body cannot totally separate from the valve body and balloon.
  • the tail anchor section comprises an elongate body connected at a first end to the head section and having extending from a second end retaining means which in-use engage the balloon or first end of the valve body and prevent the switch body from exiting the passage through the second end but do not prevent fluid flow through the passage.
  • the tail anchor section comprises a flexible connector that connects the head section to the valve body or balloon.
  • the flexible connector is a thread.
  • the switch body is positioned in the passage and dimensioned to block fluid flow through the passage, and the biodegradable securing means is attached to, abuts or engaged with the valve body and prevents the switch body from exiting the passage.
  • the biodegradable securing means extends over the valve second end.
  • the biodegradable securing means is attached to the switch body.
  • the biodegradable securing means is attached to an external face of the valve body, hi other embodiments, the biodegradable securing means is attached to the inner wall of the passage. In certain embodiments, the biodegradable securing means is attached to the switch body.
  • the biodegradable securing means is at least one of the group consisting of: hook, bar, and strap.
  • the biodegradable securing means comprises 2, 3, 4, 5 and 6 hooks.
  • the biodegradable securing means comprises a layer extending over a cross-section of the passage and located in the passage between the valve second end and the switch body.
  • the biodegradable securing means is preferably attached to the inner wall of the passage and to the switch body.
  • the biodegradable securing means comprises a layer located in the passage between the valve second end and the switch body, the layer attached to the inner wall of the passage and extending over a cross-section of the passage.
  • the switch body is positioned in the passage and dimensioned to block fluid flow through the passage, and the valve body additionally comprises at least one arm, rim, recess, or securing means, the biodegradable securing means comprising a layer located in said passage between the valve second end and the switch body, the layer being engaged with or attached to the at least one arm, rim, recess or securing means so as to prevent the switch body from exiting the passage through the valve second end.
  • biodegradable securing means extends over a cross- section of the passage.
  • the layer takes the form of a plate extending across the passage.
  • the switch body comprises a sprung valve which has open and closed positions and which urges to the open position
  • the biodegradable securing means comprises closure means which retain the sprung valve in the closed position
  • the sprung valve is a duckbill valve
  • the closure means comprise a clamp.
  • the switch body comprises a flexible body defining a lumen extending from and in fluid communication with the passage and movable between:
  • a second open state in which fluid flow can occur through said flexible body comprises a body secured on, in or to said valve body, in a non-degraded state said biodegradable securing means causing said flexible body to be in said first closed state, and in a degraded state said biodegradable securing means not causing said flexible body to be in said first closed state.
  • said flexible body in said first closed state said flexible body is compressed or folded or has a kink in it.
  • said flexible body is non-compressed or extended.
  • the biodegradable securing means allows the flexible body to be in the second extended state.
  • the biodegradable securing means In the non-degraded state, movement from the first compressed state to the second extended state is prevented by the biodegradable securing means.
  • the biodegradable securing means In the degraded state, the biodegradable securing means does not block movement of the flexible body and so it is free to move to the second extended state.
  • the switch body comprises a flexible body defining a lumen extending from and in fluid communication with the passage and movable between:
  • the biodegradable securing means comprises a body secured about the flexible body and retaining the flexible body in the first closed state, in a non-degraded state the biodegradable securing means retaining the flexible body in the first closed state, and in a degraded state the biodegradable securing means not causing the flexible body to be in the first closed state.
  • the biodegradable securing means allows the flexible body to be in the second open state.
  • the flexible body comprises a flexible tube.
  • the biodegradable securing means comprises a biodegradable clip, tie or thread.
  • the biodegradable securing means causes the flexible body to be in a folded state, the fold in the flexible body causing it to be closed to fluid flow.
  • the flexible body In the degraded state, the flexible body is free to move to an unfolded state and the flexible body to be open to fluid flow.
  • the flexible body is surrounded by the valve body.
  • the biodegradable securing means compresses the flexible body, causing it to be closed to fluid flow.
  • the flexible body In the degraded state, the flexible body is not compressed and is open to fluid flow.
  • the gastric balloon device can be inserted surgically, for example with the use of an endoscope type device.
  • the self-deflating gastric balloon device is an orally ingestible gastric balloon device.
  • the self-deflating gastric balloon device is provided in an orally ingestible encapsulated form.
  • the encapsulation material is degradable in stomach fluids. More preferably, it is rapidly degradable in stomach fluids, for example within a period of about 1, 2, 3, 4 or 5 minutes.
  • the capsule degrades in about one minute.
  • the capsule is a gelatine.
  • an externally inflatable gastric balloon device comprising:
  • a balloon defining a balloon volume
  • fluid inlet valve means comprising a filling connector comprising a connecting tube connected to said fluid inlet valve means; wherein said connecting tube is in fluid communication with said balloon volume via said fluid inlet valve means, said connecting tube being in-use separable from said fluid inlet valve means.
  • the self-deflating gastric balloon devices of the present invention additionally comprise: (a) fluid inlet valve means; and
  • a filling connector comprising a connecting tube connected to said fluid inlet valve means; wherein said connecting tube is in fluid communication with said balloon volume via said fluid inlet valve means, said connecting tube being in-use separable from said fluid inlet valve means.
  • the connecting tube is flexible.
  • Preferable materials include polyurethane and silicone.
  • the connecting tube is made of a material which can undergo significant longitudinal stretching (for example at least 5, 6, 7, 8, 9 or 10%) at the tensions that will be applied to it in-use (for example resulting from the connecting tube being pulled on to separate it from the fluid inlet valve means
  • an additional material such as a thread may be provided which does not undergo significant longitudinal stretching at those tensions.
  • Suitable materials include nylon and Kevlar (RTM).
  • the connecting tube is provided with a stretch-resistant material extending along its longitudinal length.
  • fluid supply means examples include a syringe, hand pump, motorised pump, compressed gas supply, and compressed gas cylinder, each having a supply of liquid or gas to be passed to the interior of the balloon via the connecting tube.
  • the fluid supply means is provided with a supply of fluid.
  • the connecting tube is provided with an in-use non-swallowable collar. More preferably, the collar is engageable with the connecting tube without preventing fluid flow along the connecting tube past the collar.
  • the connecting tube is provided with a scale.
  • the collar can be engaged with the connecting tube at a suitable position such that the patient can swallow the gastric balloon device up until the collar contacts their mouth and further swallowing of the connecting tube is prevented. At this point, the patient will have swallowed the correct length of connecting tube for the gastric balloon device to be located in their stomach, ready for inflation.
  • the collar is engaged with the connecting tube by an adhesive. More preferably, the collar is self-adhesive.
  • the fluid inlet valve is a one-way valve.
  • the fluid inlet valve is a self-sealing valve such as a self-sealing gasket valve.
  • a self-sealing gasket valve such as a self-sealing gasket valve.
  • Suitable materials for self-sealing gasket valves include silicone.
  • the fluid inlet valve means (also referred to herein as a “base unit”) is located in a housing (also referred to herein as a “base unit housing”) defining an opening at one end that is in fluid communication with the balloon volume.
  • the filling connector comprises a cannula, more preferably a rigid cannula.
  • the cannula passes through the self-sealing gasket valve and is resistant to the pressures exerted by the self-sealing gasket valve such that fluid can flow through the self-sealing gasket valve via the cannula.
  • the cannula is retained in the self-sealing gasket valve by a friction fit.
  • the fluid inlet valve is a self-sealing gasket valve
  • it preferably takes the form of an expandable septum, for example made from silicone.
  • the septum can be pressure formed in a housing defining an opening at one end that in-use will be in fluid communication with a balloon volume.
  • a rigid cannula which is capable of withstanding the pressures exerted upon it by the septum material is inserted into the septum so that it is in fluid communication with the opening in the base unit housing. The cannula is retained in place and in fluid communication with the opening in the base unit housing and thus with the balloon volume due to the septum material causing a friction fit.
  • the balloon volume is filled via the cannula and connecting tube, and the cannula is removed by pulling on the connecting tube - the inflated balloon is pulled upwards but its movement is restricted as it contacts the walls of the upper stomach, causing the cannula to be pulled from the septum.
  • the septum material expands to fill the gap left by the cannula and thus seal the septum, preventing further fluid flow through the fluid inlet valve means and the opening in the housing.
  • the gastric balloon device and/or any connecting tube is coated with or comprises a lubricant.
  • Suitable lubricants include polyethylene glycol which can be incorporated into any connecting tube material, and polyethylene oxide which can be used as a lubricant coating. Other lubricants will be readily apparent to one of ordinary skill in the art.
  • the connecting tube is at least partially contained within a wrapper.
  • the wrapper is rapidly-dissolving in water or saliva. This makes the gastric balloon device easy to handle and allows a patient to easily position the wrapped connecting tube with their tongue at the back of their mouth.
  • Preferable wrapper materials include thin sheets of a rapidly dissolving gelatine.
  • the filling connector in-use becomes separable from the fluid inlet valve means in stomach fluids, and otherwise resists separation from the fluid inlet valve means.
  • the filling connector resists separation from the fluid inlet valve means in a non-liquid environment.
  • the gastric balloon device is preferably provided encapsulated in a material that rapidly dissolves or degrades in stomach fluids.
  • the gastric balloon device is provided in the form of a capsule.
  • the balloon is folded up and/or compressed in the capsule.
  • the encapsulation material retains the filling connector or connecting tube.
  • the connecting tube or filling connector is provided with an at least one protrusion. More preferably, the at least one protrusion contacts and is retained by the encapsulation material. In certain embodiments, the at least one protrusion is located extending into the encapsulation material. Preferably, the at least one protrusion is located internal to the gastric balloon device relative to an outer surface of the encapsulation material. Preferably, the at least one protrusion is located inwards of the gastric balloon device relative to an inner surface of the encapsulation material. In-use this causes additional resistance to the separation of the connecting tube from the fluid inlet valve means and can help prevent accidental separation of the connecting tube from the fluid inlet valve means. When the capsule is not degraded, separation of the connecting tube from the fluid inlet valve means is additionally resisted by frictional resistance between the capsule and the at least one protrusion.
  • the fluid inlet valve means comprises a stainless steel collar surrounding a silicone septum having extending through it a rigid cannula of a filling connector.
  • the connecting tube is then connected to the cannula and has extending from it at a protrusion which contacts and is retained by the encapsulation material.
  • the protrusion is internal to the gastric balloon device relative to an inner (i.e. inwards-facing) surface of the encapsulation material.
  • this helps prevent separation of the filling connector from the balloon during handling and swallowing, after which the capsule dissolves or is degraded.
  • the capsule dissolves or is degraded to allow the balloon to be filled and expand.
  • the connecting tube becomes readily separable from the balloon (for example, after a period of at least one minute, e.g. about 1, 2, 3, 4, or 5 minutes) and in-use is separated from the balloon and is retrieved from the patient.
  • the fluid inlet valve is combined with the (deflation) valve means.
  • the fluid inlet valve is preferably self-sealing.
  • the switch body comprises the fluid inlet valve.
  • the connecting tube or filling connector is connected to a self-sealing fluid inlet valve which forms the switch body and is secured by the biodegradable securing means.
  • the balloon volume is filled via the connecting tube, and the connecting tube or filling connector is then separated from the fluid inlet valve which seals to prevent further fluid flow through it.
  • Also provided according to the present invention is a method of administering a gastric balloon device to a patient, comprising the steps of:
  • such a method additionally comprises the step of determining a reference length of the patient's oesophagus, the step of providing the patient with a gastric balloon device according to the present invention comprising selecting or adjusting the length or swallowable length of the gastric balloon to correspond to the determined reference length of said patient's oesophagus.
  • Also provided according to the present invention is a method of providing a patient with a gastric balloon device, comprising the steps of:
  • the method further comprises the step of removing the deflated self-deflating gastric balloon device.
  • the method further comprises the step of allowing the patient to excrete the deflated self-deflating gastric balloon device.
  • the balloon deflates with assistance from the natural physiological contractions of the stomach which cause the balloon to be emptied and to collapse and crush the balloon, allowing it to pass through the pyloric sphincter and through the intestine to be excreted.
  • such a method is a method of appetite suppression or weight control.
  • Figure 1 shows a plan view of a self-deflating gastric balloon device plus connecting tube and filling means;
  • Figure 2 shows a close-up cross-section along lines I-I, showing the base unit;
  • Figure 3 shows a close-up perspective cut-away view of the collar, septum and cannula of the self-deflating gastric balloon device of Figure
  • Figure 4 shows a perspective view of the self-deflating gastric balloon device in an inflated state
  • Figure 5 shows a fluid inlet with an elastomeric septum used as fluid inlet valve means
  • Figure 6 shows the fluid inlet of Figure 5, with the cannula partially removed
  • Figure 7 shows the fluid inlet of Figure 5 with the cannula wholly removed and further fluid flow through the elastomeric septum blocked;
  • Figure 8 shows a cross-section through a first valve means
  • Figure 9 shows a perspective view of a second valve means
  • Figure 10 shows a cross-section through a third valve means
  • Figure 11 shows a cross-section through a fourth valve means
  • Figure 12 shows a cross-section through a fifth valve means
  • Figure 13 shows a cross-section through a sixth valve means
  • Figure 14 shows a cross-section through a seventh valve means
  • Figure 15 shows a cross-section through an eighth valve means
  • Figure 16 shows a plan view of a self-deflating gastric balloon device plus connecting tube and filling means, the connecting tube being wrapped in a rapidly dissolving thin gelatine film;
  • Figure 17 shows the fluid inlet of Figure 17 with a modified connecting tube incorporating a tubing enlargement.
  • a patient who is to be administered self-deflating gastric balloon device 10 is first measured and comparison made to reference tables to determine a reference distance between their mouth and stomach, and thus the distance that device 10 must to travel to be located in their stomach. This also determines a reference distance between their mouth and the pyloric sphincter, and thus the distance beyond which device 10 must not travel in order to avoid blocking the pyloric sphincter or entering the duodenum.
  • Device 10 is dimensioned to be conveniently swallowable by a patient.
  • Connecting tube 20 is a thin-walled small-bore polyurethane tube with an outer diameter of about 0.35mm and an internal diameter of about 0.29mm.
  • connecting tube 20 To prevent longitudinal stretching of connecting tube 20 when mechanical force is exerted upon it, it incorporates a Kevlar (RTM) thread (not shown) extending along its full length.
  • RTM Kevlar
  • Connecting tube 20 is manufactured incorporating polyethylene glycol to make it hydrophilic and in-use lubricious and swallowable.
  • connecting tube 20 is provided wrapped and bundled in a rapidly-dissolving wrapper 25, which is made from a thin sheet of gelatine and which is simple and easy to swallow and which upon contact with saliva dissolves to allow connecting tube 20 to extend and self-deflating gastric balloon device 10 to pass to the stomach.
  • Attached to device 10 is connecting tube 20 and filling syringe 30 containing fluid 40.
  • the self-deflating gastric balloon device is to be inflated with fluid 40.
  • a compressed gas cylinder 100 is provided and the self- deflating gastric balloon device 10 is inflated with gas.
  • Device 10 comprises a gelatine capsule 50 containing within it folded and compressed balloon 60 having at one end valve means 70 and at another end base unit housing 140 and base unit 80 from which extends cannula 90 which is connected to connecting tube 20.
  • the saliva of the patient wets gelatine capsule 50, making it easily swallowable.
  • device 10 is manufactured with balloon 60, valve means 70, base unit housing 140 and elastomeric septum 430 (base unit 80) assembled and compressed.
  • Cannula 90 has a needle tip and is slid through elastomeric septum 430, in the process defining slit 420.
  • Connecting tube 440 is then placed over cannula 90 such that fluid can flow through connecting tube 440 and cannula 90 into balloon volume 200.
  • Gelatine capsule 50 is provided in two halves, a first half having no openings, and a second half defining an opening through which cannula 90 and connecting tube 440 can fit. The first half is then placed over the valve means 70 end, and the second half is slid along connecting tube 440 over the base unit housing 140 end until it contacts tubing enlargement 450, and the two ends are then joined together.
  • Filling syringe 30 is in fluid communication with the interior volume of balloon 60 via connecting tube 20, and cannula 90.
  • elastomeric septum 430 (base unit 80) is formed and cured in base unit housing 140.
  • Elastomeric septum 430 operates as a self-sealing gasket valve.
  • cannula 90 extending through septum 430 ( Figure 5) it is in fluid communication with balloon volume 200 and is retained by a friction fit with septum 430.
  • a gastric balloon device 10 with a suitable length connecting tube 20 is selected and connected to filling syringe 30.
  • Gastric balloon device 10 is then swallowed by the patient and is passed to the stomach.
  • connecting tube 20 is not of sufficient length to allow that to occur.
  • gelatine capsule 50 dissolves within 1-2 minutes and balloon 60 can be inflated.
  • Filling syringe 30 is used to fill balloon 60 with a desired volume of fluid 40, causing it to expand and reduce the stomach volume available to the patient, thus acting as an appetite suppressant.
  • balloon 60 has a diameter of about 100mm.
  • connecting tube 20 is pulled, causing balloon 60 to be pulled and to contact the wall of the upper stomach, preventing its further movement.
  • the pulling force exerted on connecting tube 20 causes cannula 90 to be pulled out of slit 420 which it previously created in septum 430, which self-seals behind it ( Figure 6).
  • cannula 90 has been wholly pulled from slit 420 in septum 430 ( Figure 7), it can continue to be pulled from the patient and is retrieved from the oesophagus of the patient together with connecting tube 20.
  • Balloon 60 is self-deflating, and this deflation is achieved by valve means 70.
  • valve means 70 comprises valve body 170 defining passage 180 having a second end 190 located external to balloon volume 200 and a first end 210 internal to balloon volume
  • Valve means 70 is attached to balloon 60 and also comprises degradable switch means 220 which controls fluid flow through passage 180, such that with degradable switch means 220 in a non-degraded state fluid flow through passage 180 is prevented, and with degradable switch means 220 in a degraded state fluid flow through passage
  • valve means 70 A first embodiment of valve means 70 is shown in Figure 8 in which switch means 220 comprises a switch body and biodegradable securing means, namely plug 230 and biodegradable hooks 240.
  • Plug 230 is positioned in passage 180 and dimensioned to block fluid flow through passage 180, and biodegradable hooks 240 made of gelatine are attached to external surface 250 of valve body 170 and to plug 230, preventing plug 230 from exiting passage 180.
  • the biodegradable hooks 240 are absorbed by the stomach fluid over a period of about two months. Whilst the biodegradable hooks 240 remain mechanically sound, movement of plug 230 from passage 180 is prevented and thus fluid flow through passage 180 is cannot occur. When biodegradable hooks 240 lose their mechanical integrity, plug 230 is able to move relative to passage 180 and exits it into the stomach. At this point, fluid 40 is able to flow from balloon volume 200 through passage 180, and is caused to do so either by a fluid pressure created when balloon 60 was filled, or due to a mechanical pressure exerted by the stomach.
  • first non-degraded state switching occurs between a first non-degraded state and a second degraded state.
  • first non-degraded state fluid flow is prevented, whereas in the second degraded state, fluid flow can occur.
  • this fluid flow in the second degraded state can be considered to be a free fluid flow, and is distinct from prior art devices which during the degradation process allow a continually increasing amount of fluid flow to occur and do not provide the binary fluid flow states of the present invention.
  • valve means 70 shown in Figure 9 operation is as per Figure 8, except that instead of biodegradable hooks 240, biodegradable strap 260 is provided which is attached to external surface 250 of valve body 170 and abuts plug 230, preventing plug 230 from exiting passage 180.
  • operation is as per Figure 8.
  • movement of plug 230 along passage 180 to balloon volume 200 is prevented by pressure exerted upon it by fluid 40 in the balloon volume, either due to fluid 40 being inserted into balloon 60 at an elevated pressure relative to stomach fluids or due to the stomach exerting a mechanical pressure upon balloon 60.
  • biodegradable strap 260 is replaced with a biodegradable bar which is attached to and engaged with a surface feature of valve body 170 and which is attached to plug 230.
  • a self-deflating gastric balloon device is supplied as per the second embodiment, but with biodegradable strap 260 attached to the inner wall of passage 180.
  • plug 270 is located in passage 180 and blocks fluid flow through passage 180.
  • plug 270 is recessed at its radial periphery, and a generally ring shaped biodegradable layer 280.
  • Biodegradable layer 280 is attached to valve body 170 and to plug 270 and has an external surface 290 which in use in the stomach of a patient is exposed to stomach fluids and is degraded.
  • fluid flow through passage 180 is prevented when degradable switch means 220 is in the non-degraded state, whereas with degradable switch means 220 in the degraded state, fluid flow can occur through passage 180 by fluid pressure causing plug 270 to exit passage 180 into the stomach.
  • switch means 220 comprises plug 230 and biodegradable securing means 300.
  • valve body 170 is recessed to define a rim 310 (also referred to as a "dado").
  • Biodegradable securing means 300 is located in passage 180 between plug 230 and second end 190 so as to prevent plug 230 from exiting passage 180 through second end 190.
  • Biodegradable securing means 300 is engaged with rim 310 and extends across the cross-section of passage 180.
  • valve body 170 is provided with arms and securing means, and the biodegradable securing means is engaged with them. In other embodiments, it is attached to them. In other embodiments, the biodegradable securing means does not extend over the whole of a cross-section of passage 180, but still prevents plug 230 from exiting passage 180 through second end 190.
  • valve body is not recessed and instead of biodegradable securing means 300 being engaged with a rim, instead it is attached to the inner wall of passage 180 and extends over a cross section of passage 180.
  • switch means 220 comprises head section 320 and tail anchor section 330 comprising elongate body section 340 and anchor 350 which in- use abuts the first end 210 of valve body 170 and prevents switch means 220 from exiting passage 180 through second end 190 but does not prevent fluid flow through passage 180.
  • valve body 170 is recessed to define a rim 310.
  • Switch means 220 also comprises biodegradable securing means 300 located in passage 180 between head section 320 and second end 190 so as to prevent head section 320 from exiting passage 180 through second end 190.
  • Biodegradable securing means 300 is attached to rim 310 and extends across a part of the cross-section of passage 180.
  • tail anchor section 330 is replaced with a flexible thread which is attached to the underside of valve body 170 beyond first end 210 and which prevents head section 320 from becoming separated from the rest of self- deflating intragastric balloon device 10.
  • switch means 220 comprises duckbill valve 360 and biodegradable clamp 370.
  • Duckbill valve 360 is movable between (i) an open state in which the valve leaves 380 are apart and in which fluid flow can occur through the valve 360, and (ii) a closed state in which the valve leaves 380 are brought together and in which fluid flow cannot occur through the valve 360.
  • Duckbill valve 360 is sprung and urges to the open position. In order to close duckbill valve 360, external force must be exerted to bring together valve leaves 380.
  • biodegradable clamp 370 which clamps valve leaves 380 in the closed position.
  • switch body 220 comprises (i) flexible tube 390 defining a lumen therein extending within and from and in fluid communication with passage 180, and (ii) biodegradable securing means 400.
  • Valve body 170 is recessed at the second end 190 of passage 180 to define (i) a volume in which flexible tube 390 can fit in a compressed state, particularly in a folded state, and (ii) a rim to which is attached biodegradable securing means 400 which extends across the whole cross-section of passage 180.
  • flexible tube 390 is caused to be compressed and folded by biodegradable securing means 400, meaning that fluid flow through flexible tube 390 is blocked.
  • flexible tube 390 In use, upon degradation of biodegradable securing means 400 in the stomach of a patient, flexible tube 390 is able to go to (and is caused to go to by fluid pressure exerted by fluid 40 in balloon volume 200) a second unfolded (extended) non- compressed state in which fluid flow can occur through it.
  • this embodiment provides an extremely simple and convenient self-deflating gastric balloon device 10.
  • switch body 220 comprises flexible tube 390 defining a lumen therein extending within and from and in fluid communication with passage 180.
  • Switch means 220 also comprises biodegradable tie 410.
  • Valve body 170 is recessed at the second end 190 of passage 180 to define a volume in which flexible tube 390 can fit in both a folded state and an extended state, thus allowing flexible tube 390 to extend and allow fluid flow through flexible tube 390 when switch means 220 is in a degraded state and not be blocked by flexible tube being pressed against the patient's stomach wall.
  • flexible tube 390 is caused to be compressed and folded to place it in a first closed state, and is held in that form by biodegradable tie 410, meaning that fluid flow through flexible tube 390 is blocked.
  • flexible tube 390 In use, upon degradation of biodegradable tie in the stomach of a patient, flexible tube 390 is able to go to (and is caused to go to by fluid pressure exerted by fluid 40 in balloon volume 200) a second unfolded open state in which fluid flow can occur through it.
  • this embodiment provides an extremely simple and convenient self-deflating gastric balloon device 10.
  • base unit 460 comprises stainless steel collar 110 which has an axial length of 4mm and having on its external surface an absorbable coating 480 of polylactic co-glycolide (PLGA), and located on its inward surface a silicone elastomeric septum 430 which is a self-sealing gasket valve and which contains rigid cannula 90.
  • Base unit 80 additionally comprises base unit housing 470.
  • Cannula 90 traverses the length of elastomeric septum 430.
  • Connecting tube 440 has a tubing enlargement 450 contained within gelatine capsule 50 and which helps prevent separation of cannula 90 from elastomeric septum 430.
  • Connecting tube 440 has a tubing enlargement 450 contained within gelatine capsule 50 and which helps prevent separation of cannula 90 from elastomeric septum 430.
  • Stainless steel collar 110, absorbable coating 480 and elastomeric septum 430 are contained within combined base unit housing and valve body 470.
  • Balloon 60 is discontinuous over the external surface 160 of valve body 170 and in-use allows stomach fluids to come into contact with biodegradable coating 480 (and similar parts 240, 260, 300, 370, 400, 410 above).
  • absorbable PLGA coating 480 is degraded by stomach fluids and finally with absorbable coating 480 mechanically unsound, the switch means enters the degraded state and pressure exerted by fluid contained within balloon volume 200 causes elastomeric septum 430 and stainless steel collar 110 to be ejected from the passage defined by combined base unit housing and valve body 470, allowing fluid flow through the passage and balloon 60 to deflate.
  • this embodiment also provides an extremely simple and convenient self-deflating gastric balloon device.
  • self-deflating gastric balloon device 10 is orally ingestible, and a patient is provided with a gastric balloon device 10 by: (i) orally ingesting gastric balloon device 10; (ii) gastric balloon device 10 being inflated with fluid 40 from filling syringe
  • Such a method is a method of appetite suppression and weight control.
  • valve means 80 base unit

Landscapes

  • Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Nursing (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgical Instruments (AREA)

Abstract

La présente invention concerne de nouveaux dispositifs à ballons gastriques auto-dégonflables améliorés, plus particulièrement des dispositifs à ballons gastriques auto-dégonflables ingérés par voie orale.
PCT/EP2008/009603 2007-11-09 2008-11-03 Dispositif à ballon gastrique auto-dégonflable WO2009059802A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99630407P 2007-11-09 2007-11-09
US60/996,304 2007-11-09

Publications (1)

Publication Number Publication Date
WO2009059802A1 true WO2009059802A1 (fr) 2009-05-14

Family

ID=40292566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/009603 WO2009059802A1 (fr) 2007-11-09 2008-11-03 Dispositif à ballon gastrique auto-dégonflable

Country Status (1)

Country Link
WO (1) WO2009059802A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202291B1 (en) 2011-01-21 2012-06-19 Obalon Therapeutics, Inc. Intragastric device
WO2013126593A1 (fr) 2012-02-21 2013-08-29 Allurion Technologies, Inc. Procédés et dispositifs pour le déploiement d'un implant temporaire dans le corps et pour son élimination
WO2015066545A1 (fr) 2013-11-01 2015-05-07 Allurion Technologies, Inc. Méthodes et dispositifs pour le déploiement d'un implant temporaire dans le corps et pour son retrait
EP3117865A1 (fr) * 2011-01-21 2017-01-18 Obalon Therapeutics, Inc. Dispositif intragastrique
US9849018B2 (en) 2012-02-21 2017-12-26 Allurion Technologies, Inc. Ingestible delivery systems and methods
CN108158705A (zh) * 2017-12-18 2018-06-15 常州至善医疗科技有限公司 一种用于球囊系统的连接和释放结构
US10182932B2 (en) 2012-02-21 2019-01-22 Allurion Technologies, Inc. Methods and devices for deploying and releasing a temporary implant within the body
US10335303B2 (en) 2015-12-07 2019-07-02 Obalon Therapeutics, Inc. Intragastric device
WO2019136227A1 (fr) * 2018-01-06 2019-07-11 Barix Medical Corp., a Delaware Corporation Système de ballonnet gastrique implantable simplifié avec temporisateur d'auto-dégonflage
US10537453B2 (en) 2015-12-16 2020-01-21 Obalon Therapeutics, Inc. Intragastric device with expandable portions
US10874537B2 (en) 2008-10-16 2020-12-29 Obalon Therapeutics, Inc. Intragastric volume-occupying device and method for fabricating same
US11098813B2 (en) 2018-07-06 2021-08-24 Allurion Technologies, Inc. Binary fluid control valve system
US11497900B2 (en) 2018-12-13 2022-11-15 Allurion Technologies, Inc. Enhanced fluid delivery system
US11559418B2 (en) 2018-02-26 2023-01-24 Allurion Technologies, Inc. Automatic-sealing balloon-filling catheter system
US11819433B2 (en) 2016-11-04 2023-11-21 Reshape Lifesciences Inc. Pressure control system for intragastric device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171768A1 (en) * 2002-03-07 2003-09-11 Mcghan Jim J. Self-deflating intragastric balloon
WO2006020929A2 (fr) * 2004-08-13 2006-02-23 Phagia Technology Dispositif place dans le volume intragastrique
EP1774929A2 (fr) * 2005-10-12 2007-04-18 Sr. Wendell C. Hull Dispositif intragastrale pour le contrôle du surpoids
US20070100367A1 (en) * 2005-10-31 2007-05-03 Quijano Rodolfo C Intragastric space filler

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171768A1 (en) * 2002-03-07 2003-09-11 Mcghan Jim J. Self-deflating intragastric balloon
WO2006020929A2 (fr) * 2004-08-13 2006-02-23 Phagia Technology Dispositif place dans le volume intragastrique
EP1774929A2 (fr) * 2005-10-12 2007-04-18 Sr. Wendell C. Hull Dispositif intragastrale pour le contrôle du surpoids
US20070100367A1 (en) * 2005-10-31 2007-05-03 Quijano Rodolfo C Intragastric space filler

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11219543B2 (en) 2008-10-16 2022-01-11 Reshape Lifesciences Inc. Intragastric device
US12102547B2 (en) 2008-10-16 2024-10-01 Reshape Lifesciences Inc. Intragastric volume-occupying device and method for fabricating same
US10874537B2 (en) 2008-10-16 2020-12-29 Obalon Therapeutics, Inc. Intragastric volume-occupying device and method for fabricating same
US12090075B2 (en) 2008-10-16 2024-09-17 Reshape Lifesciences Inc. Intragastric device
US9011477B2 (en) 2011-01-21 2015-04-21 Obalon Therapeutics, Inc. Intragastric device
US8202291B1 (en) 2011-01-21 2012-06-19 Obalon Therapeutics, Inc. Intragastric device
US11779482B2 (en) 2011-01-21 2023-10-10 Reshape Lifesciences Inc. Intragastric device
US11737899B2 (en) 2011-01-21 2023-08-29 Reshape Lifesciences Inc. Intragastric device
US9468550B2 (en) 2011-01-21 2016-10-18 Obalon Therapeutics, Inc. Intragastric device
EP3117865A1 (fr) * 2011-01-21 2017-01-18 Obalon Therapeutics, Inc. Dispositif intragastrique
US9662239B2 (en) 2011-01-21 2017-05-30 Obalon Therapeutics, Inc. Intragastric device
US11974934B2 (en) 2011-01-21 2024-05-07 Reshape Lifesciences Inc. Intragastric device
US8992561B2 (en) 2011-01-21 2015-03-31 Obalon Therapeutics, Inc. Intragastric device
US9827128B2 (en) 2011-01-21 2017-11-28 Obalon Therapeutics, Inc. Intragastric device
US10773061B2 (en) 2011-01-21 2020-09-15 Obalon Therapeutics, Inc. Intragastric device
KR101806089B1 (ko) 2011-01-21 2017-12-07 오발론 테라퓨틱스 인코퍼레이티드 위내 장치
US10610396B2 (en) 2011-01-21 2020-04-07 Obalon Therapeutics, Inc. Intragastric device
US10463520B2 (en) 2011-01-21 2019-11-05 Obalon Therapeutics, Inc. Intragastric device
EP3284504A3 (fr) * 2011-01-21 2018-06-27 Obalon Therapeutics, Inc. Dispositif intragastrique
AU2017204386B2 (en) * 2012-02-21 2019-09-12 Allurion Technologies, Llc Methods and devices for deploying and releasing a temporary implant within the body
US10786379B2 (en) 2012-02-21 2020-09-29 Allurion Technologies, Inc. Methods and devices for deploying and releasing a temporary implant within the body
US10307279B2 (en) 2012-02-21 2019-06-04 Allurion Technologies, Inc. Ingestible delivery systems and methods
EP3494938A1 (fr) * 2012-02-21 2019-06-12 Allurion Technologies, Inc. Dispositifs de déploiement et de libération d'un implant temporaire dans le corps
US11766346B2 (en) 2012-02-21 2023-09-26 Allurion Technologies, Inc. Methods and devices for deploying and releasing a temporary implant within the body
WO2013126593A1 (fr) 2012-02-21 2013-08-29 Allurion Technologies, Inc. Procédés et dispositifs pour le déploiement d'un implant temporaire dans le corps et pour son élimination
EP3189817A1 (fr) * 2012-02-21 2017-07-12 Allurion Technologies, Inc. Procédés et dispositifs de déploiement et de libération d'un implant temporaire dans le corps
US10182932B2 (en) 2012-02-21 2019-01-22 Allurion Technologies, Inc. Methods and devices for deploying and releasing a temporary implant within the body
JP2015510437A (ja) * 2012-02-21 2015-04-09 アルリオン テクノロジーズ， インク． 体内で一時的なインプラントを展開および排出する方法および装置
EP2817062A4 (fr) * 2012-02-21 2015-12-30 Allurion Technologies Inc Procédés et dispositifs pour le déploiement d'un implant temporaire dans le corps et pour son élimination
US9849018B2 (en) 2012-02-21 2017-12-26 Allurion Technologies, Inc. Ingestible delivery systems and methods
US10729572B2 (en) 2012-02-21 2020-08-04 Allurion Technologies, Inc. Methods and devices for deploying and releasing a temporary implant within the body
US9827129B2 (en) 2012-02-21 2017-11-28 Allurion Technologies, Inc. Methods and devices for deploying and releasing a temporary implant within the body
CN106029013A (zh) * 2013-11-01 2016-10-12 阿勒里恩科技公司 展开和释放身体内的临时移植物的方法和设备
EP3062749A4 (fr) * 2013-11-01 2017-12-06 Allurion Technologies, Inc. Méthodes et dispositifs pour le déploiement d'un implant temporaire dans le corps et pour son retrait
WO2015066545A1 (fr) 2013-11-01 2015-05-07 Allurion Technologies, Inc. Méthodes et dispositifs pour le déploiement d'un implant temporaire dans le corps et pour son retrait
AU2014342014B2 (en) * 2013-11-01 2019-02-14 Allurion Technologies, Llc Methods and devices for deploying and releasing a temporary implant within the body
CN106029013B (zh) * 2013-11-01 2019-08-27 阿勒里恩科技公司 展开和释放身体内的临时移植物的方法和设备
US10335303B2 (en) 2015-12-07 2019-07-02 Obalon Therapeutics, Inc. Intragastric device
US10537453B2 (en) 2015-12-16 2020-01-21 Obalon Therapeutics, Inc. Intragastric device with expandable portions
US11819433B2 (en) 2016-11-04 2023-11-21 Reshape Lifesciences Inc. Pressure control system for intragastric device
CN108158705B (zh) * 2017-12-18 2024-05-28 常州至善医疗科技有限公司 一种用于球囊系统的连接和释放结构
EP3730099A4 (fr) * 2017-12-18 2021-09-15 Changzhou Panda Medical Co., Ltd. Structure de connexion et de libération pour système à ballonnet
US11931280B2 (en) 2017-12-18 2024-03-19 Changzhou Panda Medical Co., Ltd. Connecting and releasing structure for balloon system
CN108158705A (zh) * 2017-12-18 2018-06-15 常州至善医疗科技有限公司 一种用于球囊系统的连接和释放结构
WO2019136227A1 (fr) * 2018-01-06 2019-07-11 Barix Medical Corp., a Delaware Corporation Système de ballonnet gastrique implantable simplifié avec temporisateur d'auto-dégonflage
US11559418B2 (en) 2018-02-26 2023-01-24 Allurion Technologies, Inc. Automatic-sealing balloon-filling catheter system
US12109138B2 (en) 2018-02-26 2024-10-08 Allurion Technologies, Inc. Automatic-sealing balloon-filling catheter system
EP3813922A4 (fr) * 2018-07-06 2022-06-29 Allurion Technologies, Inc. Système de valve de régulation fluidique binaire
US11828377B2 (en) 2018-07-06 2023-11-28 Allurion Technologies, Inc. Binary fluid control valve system
EP4295820A3 (fr) * 2018-07-06 2024-02-28 Allurion Technologies, Inc. Système de soupape de régulation de fluide binaire
US11098813B2 (en) 2018-07-06 2021-08-24 Allurion Technologies, Inc. Binary fluid control valve system
US11497900B2 (en) 2018-12-13 2022-11-15 Allurion Technologies, Inc. Enhanced fluid delivery system

Similar Documents

Publication Publication Date Title
WO2009059803A1 (fr) Dispositif à ballon gastrique gonflable par voie externe
WO2009059802A1 (fr) Dispositif à ballon gastrique auto-dégonflable
US20220105323A1 (en) Intragastric device
KR101805995B1 (ko) 위내 장치
JP4477624B2 (ja) 自動膨張式胃内容積占拠用具
JP6174234B2 (ja) 胃内デバイス
US8657885B2 (en) Pyloric valve obstructing devices and methods
US6994095B2 (en) Pyloric valve corking device and method
US9642735B2 (en) Pyloric valve corking device
US10335303B2 (en) Intragastric device
AU2007269591A1 (en) Shunt apparatus for treating obesity by extracting food
JP6285067B2 (ja) 胃内デバイス

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08848545

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 08.09.2010)

122 Ep: pct application non-entry in european phase

Ref document number: 08848545

Country of ref document: EP

Kind code of ref document: A1